FRANKREICH

Affluent Medical announces coverage initiation of its stock by TP ICAP Midcap.

Retrieved on: 
Mercredi, avril 10, 2024
TP, Wealth, Aix-en-Provence, Ticker, Medtech

Affluent Medical announces coverage initiation of its stock by TP ICAP Midcap.

Key Points: 
  • Affluent Medical announces coverage initiation of its stock by TP ICAP Midcap.
  • Aix-en-Provence, 28 March 2024 - 5:45 pm - Affluent Medical (ISIN: FR0013333077 – Ticker: AFME), a French clinical-phase MedTech company specializing in the international development and industrialization of innovative medical prostheses, announces today that TP ICAP Midcap has initiated coverage of its stock.
  • TP ICAP Midcap began covering the stock with a study entitled "Du baume au coeur" ("Heart-Warming"), published on 27 March 2024.
  • This initiation completes the coverage of Affluent Medical’s stock and adds to the financial analyst consensus alongside Invest Securities, Kepler Cheuvreux, and Portzamparc BNP Paribas Group.

Waga Energy increases the amount allocated to liquidity contract

Retrieved on: 
Mercredi, avril 10, 2024
AMF, EPA, Portzamparc, Cryptocurrency

The issuer is solely responsible for the content of this announcement.

Key Points: 
  • The issuer is solely responsible for the content of this announcement.
  • On April 2, 2024, Waga Energy (EPA: WAGA) signed an amendment to the liquidity contract concluded with Portzamparc-BNP Paribas on November 19, 2021 in order to allocate an additional €300,000 to the contract.
  • This arrangement, which falls within the framework of AMF decision 2021-01 of June 22, 2021 on the establishment of liquidity contracts on equity securities consistent with accepted market practice, is intended to improve share liquidity and trading conditions for investors.
  • As such, the liquidity contract position after allocation of these new funds as of April 2, 2024 is:

Waga Energy announces the launch of an accelerated bookbuild offering for a minimum amount of €45 million

Retrieved on: 
Mercredi, avril 10, 2024
EGM, Natural gas, Growth, Offering, CMA-CGM, Lazard, Partnership, Financial adviser, Sale, IPO, Risk, EPA, Investment, AMF, Calendar, Legal Advisor, Renewable natural gas, Commercial code, RNG, Security (finance)

We now own 20 units in operation, 13 under construction, and with approximately 160 projects in the pipeline.

Key Points: 
  • We now own 20 units in operation, 13 under construction, and with approximately 160 projects in the pipeline.
  • Half of these projects are located in the United States, where we have recently commenced operations at our first facility.
  • This financing will enable us to capitalize on opportunities in this strategic market, where we have won several RFPs in recent months.
  • Waga Energy intends to raise gross proceeds amounting to a minimum of €45 million from the Offering of which €18.3 million have already been committed through the Subscription Commitments.

EQS-News: Abivax publishes financial reports with the French and U.S. securities regulatory agencies

Retrieved on: 
Mercredi, avril 10, 2024
EST, Q&A, Patient, Webcast, Document, Annual report, Euronext Paris, AMF, Therapy, Cryptocurrency

Abivax publishes financial reports with the French and U.S. securities regulatory agencies

Key Points: 
  • Abivax publishes financial reports with the French and U.S. securities regulatory agencies
    The issuer is solely responsible for the content of this announcement.
  • The Universal Registration Document includes the 2023 annual financial report, the management report including the report on corporate governance, as well as the reports of the statutory auditors.
  • The Abivax management will give an overview of the Company’s 2023 highlights and projects going forward, followed by a live Q&A session.
  • To participate and ask questions during the webcast, please register via the Abivax website .

Revenue for the first quarter of 2024

Retrieved on: 
Mercredi, avril 10, 2024
Marketing, CPF, Growth, Policy, Face, State

This situation, which has already been observed in previous financial years, is repeated at the start of 2024.

Key Points: 
  • This situation, which has already been observed in previous financial years, is repeated at the start of 2024.
  • In addition, the reduction in marketing investment in CPF in 2023 helped optimize the profitability of this sales channel, but slowed order intake, which is a source of future revenue.
  • The first quarter of 2023 also saw exceptional growth of 80% in sales generated by learners self-financing their training, establishing a high basis for comparison for the first quarter of 2024.
  • To register to the Company’s newsletter and receive the latest information on lePERMISLIBRE, visit : http://eepurl.com/hrySr P

Kaufman & Broad SA: 1ST QUARTER 2024 RESULTS

Retrieved on: 
Mercredi, avril 10, 2024
KB Home, Backlog, Consolidated, Policy, Acquisition, ABIS, Shareholder, Housing, VAT, Apartment, Total, Commercial property, Clothing

Net cash (c ) : €190.2M vs. € 121.6M

Key Points: 
  • Net cash (c ) : €190.2M vs. € 121.6M
    Financial capacity : €615.3M vs. €542.7M
    Main development indicators (end Feb. 2024 vs. end Feb. 2023)
    Total backlog : 2,586.1 vs. €2,890.4M
    Kaufman & Broad SA today announces its results for the 1st quarter of fiscal 2024 (from December 1st to 29th February 2024).
  • In the 1st quarter of 2024, housing orders amounted to €252.7M (including VAT), up 7.9% from €234.1M in 2023.
  • The take up period [1] was 4.1 months 2024, 1st quarter, down of 2.9 months from 6.9 months in 2023.
  • As of the 1st quarter of 2024, Kaufman & Broad had 126 housing programmes in the process of being marketed, representing 1,517 housing units (143 programmes and 2,360 housing units as of the end of February 2023).

2CRSi SA: Monthly information regarding the total number of voting rights and shares comprising the share capital as of March 30, 2024

Retrieved on: 
Mercredi, avril 10, 2024
Treasury

2CRSi SA: Monthly information regarding the total number of voting rights and shares comprising the share capital as of March 30, 2024

Key Points: 
  • 2CRSi SA: Monthly information regarding the total number of voting rights and shares comprising the share capital as of March 30, 2024
    Dissemination of a French Regulatory News, transmitted by EQS Group.
  • The issuer is solely responsible for the content of this announcement.
  • Monthly information regarding the total number of voting rights and shares comprising the share capital as of March 30, 2024
    1 Number of exercisable voting rights = total number of voting rights attached to the total number of shares minus the number of shares deprived of voting rights (treasury shares, etc.
  • ).

2CRSi announces that its subsidiary 2CRSi UK Ltd T/A Tranquil IT has signed a contract for 500 + servers with one of its existing customers.

Retrieved on: 
Mercredi, avril 10, 2024
Pleasure, Sport, News, Airline

2CRSi announces that its subsidiary 2CRSi UK Ltd T/A Tranquil IT has signed a contract for 500 + servers with one of its existing customers.

Key Points: 
  • 2CRSi announces that its subsidiary 2CRSi UK Ltd T/A Tranquil IT has signed a contract for 500 + servers with one of its existing customers.
  • Dissemination of a French Regulatory News, transmitted by EQS Group.
  • 2CRSi announces that its subsidiary 2CRSi UK Ltd T/A Tranquil IT has signed a contract for 500 + servers with one of its existing customers.
  • Manchester (UK), March 20, 2024, 2CRSI UK Ltd, a leading designer and manufacturer of rugged industrial computers, announces that it has secured a new contract to manufacture over 500 rugged servers from its customer.

lePERMISLIBRE announces its 2023 annual results

Retrieved on: 
Mercredi, avril 10, 2024
Failure, Growth, Insurance, IPO, City, Workforce, Marketing, Pharmaceutical industry

However, the overall 18% price increase applied to driving hours settled cash in 2023 boosted the gross margin from traditional candidates, which rose from 27.9% in 2022 to 29.3% in 2023.

Key Points: 
  • However, the overall 18% price increase applied to driving hours settled cash in 2023 boosted the gross margin from traditional candidates, which rose from 27.9% in 2022 to 29.3% in 2023.
  • Above results do not include the €0.3m loss from lePERMISLIBRE Insurance, a newly created subsidiary fully owned by lePERMISLIBRE, and which was not consolidated for its first year of activity.
  • We must assert our operational excellence in these three areas to give a new impetus to our growth, expand our model in France and further enhance cost reductions programs started in 2023" says Lucas TOURNEL, CEO of lePERMISLIBRE.
  • The 2023 Annual Financial Report will be available on the Company's website in mid- April at the following url address: https://www.lepermislibre.fr/investors.

RESULTS OF THE COMBINED GENERAL MEETING ON APRIL 2, 2024

Retrieved on: 
Mercredi, avril 10, 2024
Notifiable disease, Euronext Growth, Mass meeting, Meeting, Therapy

RESULTS OF THE COMBINED GENERAL MEETING ON APRIL 2, 2024

Key Points: 
  • RESULTS OF THE COMBINED GENERAL MEETING ON APRIL 2, 2024
    RESULTS OF THE COMBINED GENERAL MEETING ON APRIL 2, 2024
    Paris (France) and Cambridge (Massachusetts, USA), April 04, 2024 – 11:00pm CET – Biophytis SA (Nasdaq CM : BPTS, Euronext Growth Paris : ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics for age-related diseases, announces the approval of all the resolutions presented by the Company and falling within the remit of the Ordinary and Extraordinary General Meeting.
  • Thanks to the mobilization of shareholders, the Meeting could be held with a quorum of almost 30% of the shareholders present or represented.
  • The resolutions, which notably included a renewal of the usual financial delegations granted to the Company, were all approved.
  • The results of the votes are available on the Biophytis website in the "Investors / General Meetings" section.